中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
1期
4-6
,共3页
急性冠状动脉综合征%血管成形术,气囊,冠状动脉%C反应蛋白%血管性血友病因子%降脂药
急性冠狀動脈綜閤徵%血管成形術,氣囊,冠狀動脈%C反應蛋白%血管性血友病因子%降脂藥
급성관상동맥종합정%혈관성형술,기낭,관상동맥%C반응단백%혈관성혈우병인자%강지약
Acute coronary syndrome%Angioplasty,balloon,coronary%C-reactive protein%Von willebrand factor%Antilipemic agents
目的 观察经皮冠状动脉介入(PCI)术前短期强化他汀类药物治疗对非ST段抬高急性冠状动脉综合征(NSTE-ACS)患者高敏C反应蛋白(hs-CRP)和血管性血友病因子(vWF)的影响.方法 入选符合标准的NSTE-ACS行PCI患者100例,完全随机分为研究组和对照组,各50例.对照组和研究组均接受标准药物治疗,并分别于PCI术前开始7d开始服用辛伐他汀20 mg/次、1次/d和阿托伐他汀40 mg/次、1次/d,连用7d.术后2组均服用阿托伐他汀20 mg/次,1次/d.术日,患者均按标准程序行冠状动脉造影和PCI.检测并记录入院次日、手术当日、术后24 h血 hs-CRP和vWF水平.结果 ①PCI术当日,2组hsCRP均较本组治疗前下降；与对照组比较,研究组hs-CRP下降幅度更明显,组间差异有统计学意义[(2.1±1.6) mg/L比(3.4 ±2.3)mg/L,P＜0.05].PCI术后24 h,2组hs-CRP均较本组PCI术当日上升；研究组与对照组间的差异有统计学意义[(2.5±1.9)mg/L比(3.7±3.4) mg/L,P＜0.05].②PCI术后24 h,对照组vWF值较本组他汀类药物治疗前和PCI术当日均明显升高,与治疗后的差异有统计意义(P＜0.05)；研究组vWF值较对照组明显降低,组间差异有统计学意义[(151±54) μg/L比(204±125) μg/L,P＜0.05].结论 PCI术前短期强化他汀类药物治疗能够减低NSTE-ACS患者围术期hs-CRP水平,并减少内皮损伤.
目的 觀察經皮冠狀動脈介入(PCI)術前短期彊化他汀類藥物治療對非ST段抬高急性冠狀動脈綜閤徵(NSTE-ACS)患者高敏C反應蛋白(hs-CRP)和血管性血友病因子(vWF)的影響.方法 入選符閤標準的NSTE-ACS行PCI患者100例,完全隨機分為研究組和對照組,各50例.對照組和研究組均接受標準藥物治療,併分彆于PCI術前開始7d開始服用辛伐他汀20 mg/次、1次/d和阿託伐他汀40 mg/次、1次/d,連用7d.術後2組均服用阿託伐他汀20 mg/次,1次/d.術日,患者均按標準程序行冠狀動脈造影和PCI.檢測併記錄入院次日、手術噹日、術後24 h血 hs-CRP和vWF水平.結果 ①PCI術噹日,2組hsCRP均較本組治療前下降；與對照組比較,研究組hs-CRP下降幅度更明顯,組間差異有統計學意義[(2.1±1.6) mg/L比(3.4 ±2.3)mg/L,P＜0.05].PCI術後24 h,2組hs-CRP均較本組PCI術噹日上升；研究組與對照組間的差異有統計學意義[(2.5±1.9)mg/L比(3.7±3.4) mg/L,P＜0.05].②PCI術後24 h,對照組vWF值較本組他汀類藥物治療前和PCI術噹日均明顯升高,與治療後的差異有統計意義(P＜0.05)；研究組vWF值較對照組明顯降低,組間差異有統計學意義[(151±54) μg/L比(204±125) μg/L,P＜0.05].結論 PCI術前短期彊化他汀類藥物治療能夠減低NSTE-ACS患者圍術期hs-CRP水平,併減少內皮損傷.
목적 관찰경피관상동맥개입(PCI)술전단기강화타정류약물치료대비ST단태고급성관상동맥종합정(NSTE-ACS)환자고민C반응단백(hs-CRP)화혈관성혈우병인자(vWF)적영향.방법 입선부합표준적NSTE-ACS행PCI환자100례,완전수궤분위연구조화대조조,각50례.대조조화연구조균접수표준약물치료,병분별우PCI술전개시7d개시복용신벌타정20 mg/차、1차/d화아탁벌타정40 mg/차、1차/d,련용7d.술후2조균복용아탁벌타정20 mg/차,1차/d.술일,환자균안표준정서행관상동맥조영화PCI.검측병기록입원차일、수술당일、술후24 h혈 hs-CRP화vWF수평.결과 ①PCI술당일,2조hsCRP균교본조치료전하강；여대조조비교,연구조hs-CRP하강폭도경명현,조간차이유통계학의의[(2.1±1.6) mg/L비(3.4 ±2.3)mg/L,P＜0.05].PCI술후24 h,2조hs-CRP균교본조PCI술당일상승；연구조여대조조간적차이유통계학의의[(2.5±1.9)mg/L비(3.7±3.4) mg/L,P＜0.05].②PCI술후24 h,대조조vWF치교본조타정류약물치료전화PCI술당일균명현승고,여치료후적차이유통계의의(P＜0.05)；연구조vWF치교대조조명현강저,조간차이유통계학의의[(151±54) μg/L비(204±125) μg/L,P＜0.05].결론 PCI술전단기강화타정류약물치료능구감저NSTE-ACS환자위술기hs-CRP수평,병감소내피손상.
Objective To observe the impact of intensified statin therapy prior to percutaneous coronary intervention (PCI) on high-sensitivity C-reactive protein (hs-CRP) and von willebrand factor (vWF) in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS).Methods One hundred NSTE-ACS patients were enrolled and randomized into aggressive statin therapy or normal dose group.Both groups received standard medical therapy and the standard group received simvastatin 20 mg per day and the aggressive treatment group received atorvastatin 40 mg per day for 7 days prior to PCI.All patients received standard coronary angiography and PCI.Levels of hs-CRP and vWF were measured and compared on the procedural day and 24 hours after PCI.Results The level of hs-CRP was significantly reduced after aggressive statin treatment compared to normal dose (P ＜ 0.05).Increase of hs-CRP was observed in both groups after PCI,however the increase was more significant with normal dose (P ＜0.05).Increase of vWF level was significantly lower in the aggressive treatment group after PCI [(151 ± 54) μg/L vs (204 ± 125) μg/L,P ＜ 0.05].Conclusions Intensive statin therapy prior to PCI is effective in reducing hs-CRP and vWF levels in NSTE-ACS patients.
